Adjuvant Ablation for PeRsistent AtrIal FibrillAtion Using Dual ENergy LatticE Tip Catheter: ARIADNE-Randomized Clinical Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A prospective multi-arm parallel group randomized clinical trial to compare the efficacy of three ablation strategies in patients with persistent atrial fibrillation using using a lattice-tip catheter that can switch between RFA and PFA energy. The incremental benefit of posterior wall isolation (PWI) and mitral isthmus ablation may contribute to greater freedom from atrial fibrillation at twelve months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• 1\. Symptomatic PerAF documented by

• (1a) a physician's note indicating symptoms consistent with AF sustained longer than 7 days but less than 12 months; AND electrocardiographic evidence

• 2\. . Suitable candidate for catheter ablation.

• 3\. . Adults aged 18 - 80 years.

• 4\. . Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.

Locations
United States
New York
North Shore University Hospital
RECRUITING
Manhasset
Long Island Jewish Medical Center
RECRUITING
New Hyde Park
Kristie Coleman
RECRUITING
New York
Contact Information
Primary
Kristie Coleman, MPH, RN
kcoleman1@Northwell.edu
2124346500
Time Frame
Start Date: 2025-03-18
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 60
Treatments
Active_comparator: PVI using PFA energy
Pulmonary vein isolation using PFA energy
Active_comparator: PVI and posterior wall isolation using PFA energy
Pulmonary vein isolation and posterior wall isolation using PFA energy
Active_comparator: PVI and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
Pulmonary vein isolation and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
Related Therapeutic Areas
Sponsors
Leads: Stavros E Mountantonakis

This content was sourced from clinicaltrials.gov